349 related articles for article (PubMed ID: 29180269)
1. Dysregulation of antioxidant responses in patients diagnosed with concomitant Primary Sclerosing Cholangitis/Inflammatory Bowel Disease.
Shearn CT; Orlicky DJ; Petersen DR
Exp Mol Pathol; 2018 Feb; 104(1):1-8. PubMed ID: 29180269
[TBL] [Abstract][Full Text] [Related]
2. Cholestatic liver disease results increased production of reactive aldehydes and an atypical periportal hepatic antioxidant response.
Shearn CT; Fennimore B; Orlicky DJ; Gao YR; Saba LM; Battista KD; Aivazidis S; Assiri M; Harris PS; Michel C; Merrill GF; Schmidt EE; Colgan SP; Petersen DR
Free Radic Biol Med; 2019 Nov; 143():101-114. PubMed ID: 31377417
[TBL] [Abstract][Full Text] [Related]
3. Aberrant expression of redox regulatory proteins in patients with concomitant primary Sclerosing cholangitis/inflammatory bowel disease.
Petersen DR; Orlicky DJ; Roede JR; Shearn CT
Exp Mol Pathol; 2018 Aug; 105(1):32-36. PubMed ID: 29852184
[TBL] [Abstract][Full Text] [Related]
4. The autophagic protein p62 is a target of reactive aldehydes in human and murine cholestatic liver disease.
Shearn CT; Anderson AL; Devereux MW; Orlicky DJ; Michel C; Petersen DR; Miller CG; Harpavat S; Schmidt EE; Sokol RJ
PLoS One; 2022; 17(11):e0276879. PubMed ID: 36378690
[TBL] [Abstract][Full Text] [Related]
5. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
[TBL] [Abstract][Full Text] [Related]
6. Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease.
Henriksen EK; Jørgensen KK; Kaveh F; Holm K; Hamm D; Olweus J; Melum E; Chung BK; Eide TJ; Lundin KE; Boberg KM; Karlsen TH; Hirschfield GM; Liaskou E
J Hepatol; 2017 Jan; 66(1):116-122. PubMed ID: 27647428
[TBL] [Abstract][Full Text] [Related]
7. Elevated Nrf-2 responses are insufficient to mitigate protein carbonylation in hepatospecific PTEN deletion mice.
Petersen DR; Saba LM; Sayin VI; Papagiannakopoulos T; Schmidt EE; Merrill GF; Orlicky DJ; Shearn CT
PLoS One; 2018; 13(5):e0198139. PubMed ID: 29799837
[TBL] [Abstract][Full Text] [Related]
8. Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma.
Chung BK; Karlsen TH; Folseraas T
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1390-1400. PubMed ID: 28844951
[TBL] [Abstract][Full Text] [Related]
9. Differential carbonylation of proteins in end-stage human fatty and nonfatty NASH.
Shearn CT; Saba LM; Roede JR; Orlicky DJ; Shearn AH; Petersen DR
Free Radic Biol Med; 2017 Dec; 113():280-290. PubMed ID: 28988798
[TBL] [Abstract][Full Text] [Related]
10. What is the association of primary sclerosing cholangitis with sex and inflammatory bowel disease in Turkish patients?
Bayraktar Y; Arslan S; Saglam F; Uzunalimoglu B; Kayhan B
Hepatogastroenterology; 1998; 45(24):2064-72. PubMed ID: 9951867
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features.
Palmela C; Peerani F; Castaneda D; Torres J; Itzkowitz SH
Gut Liver; 2018 Jan; 12(1):17-29. PubMed ID: 28376583
[TBL] [Abstract][Full Text] [Related]
12. Biliary tract instillation of a SMAC mimetic induces TRAIL-dependent acute sclerosing cholangitis-like injury in mice.
Guicciardi ME; Krishnan A; Bronk SF; Hirsova P; Griffith TS; Gores GJ
Cell Death Dis; 2017 Jan; 8(1):e2535. PubMed ID: 28055006
[TBL] [Abstract][Full Text] [Related]
13. A Gradient of Intestinal Inflammation in Primary Sclerosing Cholangitis.
Wittek A; Steglich B; Casar C; Seiz O; Huber P; Ehlken H; Reher D; Wende S; Bedke T; Kempski J; Böttcher M; Bang C; Thingholm L; Krech T; Lohse AW; Sauter G; Rösch T; Franke A; Schramm C; Gagliani N; Pelczar P; Huber S
Inflamm Bowel Dis; 2024 Jun; 30(6):900-910. PubMed ID: 37540889
[TBL] [Abstract][Full Text] [Related]
14. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD.
Sabino J; Vieira-Silva S; Machiels K; Joossens M; Falony G; Ballet V; Ferrante M; Van Assche G; Van der Merwe S; Vermeire S; Raes J
Gut; 2016 Oct; 65(10):1681-9. PubMed ID: 27207975
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology and outcomes of primary sclerosing cholangitis with and without inflammatory bowel disease in an Australian cohort.
Liu K; Wang R; Kariyawasam V; Wells M; Strasser SI; McCaughan G; Corte C; Leong RW
Liver Int; 2017 Mar; 37(3):442-448. PubMed ID: 27891750
[TBL] [Abstract][Full Text] [Related]
16. Thioredoxin reductase 1 regulates hepatic inflammation and macrophage activation during acute cholestatic liver injury.
Shearn CT; Anderson AL; Miller CG; Noyd RC; Devereaux MW; Balasubramaniyan N; Orlicky DJ; Schmidt EE; Sokol RJ
Hepatol Commun; 2023 Jan; 7(1):e0020. PubMed ID: 36633484
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients.
Jørgensen KK; Grzyb K; Lundin KE; Clausen OP; Aamodt G; Schrumpf E; Vatn MH; Boberg KM
Inflamm Bowel Dis; 2012 Mar; 18(3):536-45. PubMed ID: 21456044
[TBL] [Abstract][Full Text] [Related]
18. Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis.
Gao RY; Shearn CT; Orlicky DJ; Battista KD; Alexeev EE; Cartwright IM; Lanis JM; Kostelecky RE; Ju C; Colgan SP; Fennimore BP
Mucosal Immunol; 2021 Mar; 14(2):479-490. PubMed ID: 33004979
[TBL] [Abstract][Full Text] [Related]
19. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.
Guicciardi ME; Trussoni CE; Krishnan A; Bronk SF; Lorenzo Pisarello MJ; O'Hara SP; Splinter PL; Gao Y; Vig P; Revzin A; LaRusso NF; Gores GJ
J Hepatol; 2018 Sep; 69(3):676-686. PubMed ID: 29802947
[TBL] [Abstract][Full Text] [Related]
20. A protective effect of inflammatory bowel disease on the severity of sclerosing cholangitis.
Stumme F; Steffens N; Steglich B; Mathies F; Nawrocki M; Sabihi M; Soukou-Wargalla S; Göke E; Kempski J; Fründt T; Weidemann S; Schramm C; Gagliani N; Huber S; Bedke T
Front Immunol; 2024; 15():1307297. PubMed ID: 38510236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
